Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ⅰ/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A251 in Participants With Advanced or Metastatic HER2-Expressing Solid Tumors

NCT07228247 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT07228247
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228247 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ⅰ/Ⅱa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HMPL-A251 in Participants With Advanced or Metastatic HER2-Expressing Solid Tumors
Lead sponsor
Hutchmed
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 16, 2025
Completion date
December 31, 2028
Enrollment
147 (estimated)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors, adult